BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2015-01-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1418163112PMID 25624498PMCID PMC4330752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2016cited by this paper
• Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

  2014cited by this paper
• Role of the ERas gene in gastric cancer cells

  2013cited by this paper
• Cake: a bioinformatics pipeline for the integrated analysis of somatic variants in cancer genomes

  2013cited by this paper
• A Conditional Zebrafish MITF Mutation Reveals MITF Levels Are Critical for Melanoma Promotion vs. Regression In Vivo

  2013cited by this paper
• BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

  2013cited by this paper
• A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

  2013cited by this paper
• Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.

  2013cited by this paper
• Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines

  2013cited by this paper
• A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

  2013cited by this paper
• The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

  2013influential reference
• TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma

  2013cited by this paper
• The deubiquitinase USP 9 X suppresses pancreatic ductal adenocarcinoma

  2012cited by this paper
• Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012influential reference
• Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune.

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

  2012cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012influential reference
• The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma

  2012cited by this paper
• In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

  2011cited by this paper
• ERas enhances resistance to CPT-11 in gastric cancer.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

  2011cited by this paper
• Insertional mutagenesis identifies multiple networks of co-operating genes driving intestinal tumorigenesis

  2011cited by this paper
• Mouse genomic variation and its effect on phenotypes and gene regulation

  2011cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

  2011cited by this paper
• Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells.

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric cancer.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites

  2009cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009cited by this paper
• BRafV600E cooperates with Pten silencing to elicit metastatic melanoma

  2009cited by this paper
• Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis

  2009cited by this paper
• Oncogenic Braf induces melanocyte senescence and melanoma in mice.

  2009cited by this paper
• Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

  2008influential reference
• Mutant B-RAF mediates resistance to anoikis via Bad and Bim

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008influential reference
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.

  2008cited by this paper
• Detecting Statistically Significant Common Insertion Sites in Retroviral Insertional Mutagenesis Screens

  2006cited by this paper
• Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice

  2006cited by this paper
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

  2005cited by this paper
• The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

  2005cited by this paper
• BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

  2005cited by this paper
• Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse

  2005cited by this paper
• Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system

  2005cited by this paper
• HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway.

  2004cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• Role of ERas in promoting tumour-like properties in mouse embryonic stem cells

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.

  2002cited by this paper
• Virus, cells and videotape

  2002cited by this paper
• Regulation of Bad Phosphorylation and Association with Bcl-xL by the MAPK/Erk Kinase*

  1999cited by this paper
• Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms.

  1999cited by this paper
• Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

  1999cited by this paper
• Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.

  1999cited by this paper
• Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms.

  1999cited by this paper
• Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

  1998cited by this paper
• Endothelial apoptosis in Braf-deficient mice

  1997cited by this paper
• Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

  1997cited by this paper
• Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus

  1994cited by this paper

• Investigating shared genetic architecture between pigmentation genetics and Parkinson's Disease

  2025cites this paper
• Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells

  2025cites this paper
• Inhibition of BRD4 attenuated IFNγ-induced apoptosis in colorectal cancer organoids

  2025cites this paper
• scGSDR: Harnessing gene semantics for single-cell pharmacological profiling

  2025cites this paper
• CRISPR/Cas as a Tool to Overcome Drug Resistance in Cancer: From Challenge to Opportunity.

  2025cites this paper
• Molecular Susceptibility and Treatment Challenges in Melanoma

  2024cites this paper
• KDM4B Histone Demethylase Inhibition Attenuates Tumorigenicity of Malignant Melanoma Cells by Overriding the p53‐Mediated Tumor Suppressor Pathway

  2024cites this paper
• AMBRA1 levels predict resistance to MAPK inhibitors in melanoma

  2024cites this paper
• scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network

  2024cites this paper
• CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia

  2024cites this paper
• LPCAT1 promotes melanoma cell proliferation via Akt signaling

  2024cites this paper
• Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

  2024cites this paper
• Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.

  2024cites this paper
• Advances in transposable elements: from mechanisms to applications in mammalian genomics

  2023cites this paper
• Systems Perturbation Analysis of a Large-Scale Signal Systems Perturbation Analysis of a Large-Scale Signal Transduction Model Reveals Potentially Influential Candidates for Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics Cancer Therapeutics

  2023cites this paper
• Melanoma cells with acquired resistance to vemurafenib have decreased autophagic flux and display enhanced ability to transfer resistance.

  2023cites this paper
• Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas

  2023cites this paper
• PAK1 and Therapy Resistance in Melanoma

  2023cites this paper
• RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells

  2023cites this paper
• A unique hyperdynamic dimer interface permits small molecule perturbation of the melanoma oncoprotein MITF for melanoma therapy

  2023cites this paper
• Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

  2023cites this paper
• HSPA8 Activates Wnt/β‐Catenin Signaling to Facilitate BRAF V600E Colorectal Cancer Progression by CMA‐Mediated CAV1 Degradation

  2023cites this paper
• Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma

  2022cites this paper
• Physical Interaction between Embryonic Stem Cell-Expressed Ras (ERas) and Arginase-1 in Quiescent Hepatic Stellate Cells

  2022cites this paper
• SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

  2022cites this paper
• Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance

  2022cites this paper
• Progress and Clinical Application of Single-Cell Transcriptional Sequencing Technology in Cancer Research

  2021cites this paper
• Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma

  2021cites this paper
• Autophagy Inhibition in BRAF-Driven Cancers

  2021cites this paper
• The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma

  2021cites this paper
• ERAS, a Member of the Ras Superfamily, Acts as an Oncoprotein in the Mammary Gland

  2021cites this paper
• Molecular Landscape Profile of Melanoma

  2021cites this paper
• A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2

  2021cites this paper
• Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKT

  2021cites this paper
• Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Melanoma models for the next generation of therapies.

  2021cites this paper
• Inhibition mechanism of naphthylphenylamine derivatives acting on the CDC25B dual phosphatase and analysis of the molecular processes involved in the high cytotoxicity exerted by one selected derivative in melanoma cells

  2020cites this paper
• MAPK-induced miR-29 restrains melanoma progression by targeting MAFG

  2020influential citation
• MAPK-induced miR-29 targets MAFG and suppresses melanoma development

  2020influential citation
• Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

  2020cites this paper
• BRAF mutation and its inhibitors in sarcoma treatment

  2020cites this paper
• In vivo functional screening for systems-level integrative cancer genomics

  2020cites this paper
• CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets

  2020cites this paper
• Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation

  2020cites this paper
• Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

  2020cites this paper
• PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK

  2020cites this paper
• PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

  2020cites this paper
• In vivo functional screening for systems-level integrative cancer genomics

  2020cites this paper
• Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities

  2020cites this paper
• EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells

  2019cites this paper
• Src-dependent DBL family members drive resistance to vemurafenib in human melanoma

  2019cites this paper
• Deciphering mechanisms of response and resistance in large-scale mouse cancer screens.

  2019cites this paper
• Overlapping genetic architecture between Parkinson disease and melanoma

  2019cites this paper
• Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance

  2019cites this paper
• Animal Models of Melanoma

  2019cites this paper
• A versatile ES cell-based melanoma mouse modeling platform

  2019influential citation
• Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes

  2019cites this paper
• A novel role for NFIA in restoring radiosensitivity in radioresistant NSCLC cells by downregulating the AKT and ERK pathways.

  2019cites this paper
• Mathematical Methods for Modelling Biological Heterogeneity

  2019cites this paper
• R

  2019cites this paper
• Sleeping Beauty Mouse Models of Cancer: Microenvironmental Influences on Cancer Genetics

  2019influential citation
• Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness

  2019cites this paper
• YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

  2018cites this paper
• Identification of WEE1 as a target to make AKT inhibition more effective in melanoma

  2018cites this paper
• Advances in functional genetic screening with transposons and CRISPR/Cas9 to illuminate cancer biology

  2018cites this paper
• Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation

  2018cites this paper
• Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy

  2018cites this paper
• Bad phosphorylation as a target of inhibition in oncology.

  2018cites this paper
• Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition

  2018cites this paper
• Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma

  2018cites this paper
• Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

  2018cites this paper
• The lncRNA RMEL3 protects immortalized cells from serum withdrawal‐induced growth arrest and promotes melanoma cell proliferation and tumor growth

  2018cites this paper
• The Ras-related gene ERAS is involved in human and murine breast cancer

  2018cites this paper
• Spatio-Genetic and Phenotypic Modelling Elucidates Resistance and Re-Sensitisation to Treatment in Heterogeneous Melanoma

  2018influential citation
• Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

  2018cites this paper
• The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

  2018cites this paper
• Mouse models in the era of large human tumour sequencing studies

  2018cites this paper
• Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations

  2018cites this paper
• BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers

  2018cites this paper
• Genome Editing and Engineering

  2018cites this paper
• Investigating the Roles of Fucosylation and Calcium Signaling in Melanoma Invasion

  2018cites this paper
• Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies

  2018cites this paper
• YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

  2018cites this paper
• The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.

  2017cites this paper
• Transposons As Tools for Functional Genomics in Vertebrate Models.

  2017cites this paper
• Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma

  2017cites this paper
• Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood.

  2017cites this paper
• Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers.

  2017cites this paper
• Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

  2017cites this paper
• Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.

  2017cites this paper
• The convergent roles of the nuclear factor I transcription factors in development and cancer.

  2017cites this paper
• Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells

  2017cites this paper
• P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells

  2017cites this paper
• Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.

  2017cites this paper
• Genome-wide transposon screening and quantitative insertion site sequencing for cancer gene discovery in mice

  2017cites this paper
• PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors

  2017cites this paper
• The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas

  2017cites this paper
• Signaling and Immune Regulation in Melanoma Development and Responses to Therapy.

  2017cites this paper